Analyst Research

Report Title Price
Provider: ValuEngine, Inc.
$25.00
Provider: ValuEngine, Inc.
$49.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Genmab A/S issues FY 2014 outlook below analysts' estimates


Monday, 3 Mar 2014 07:00pm EST 

Genmab A/S:Sees FY 2014 revenue of 725 - 775 million Danish crowns.Sees FY 2014 operating income continuing operations of 90 - 160 million Danish crowns.FY 2014 revenue estimate 803.20 million Danish crowns - Thomson Reuters I/B/E/S.FY 2014 EBIT estimate 170.80 million Danish crowns - Thomson Reuters I/B/E/S. 

Company Quote

529.5
-4.5 -0.84%
8:17am EDT